REFERENCES

1. Hou JL, Lai W; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 2015;23:888-905. (in Chinese)

2. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24.

3. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7.

4. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol 2016;51:473-86.

5. Lau CC, Sun T, Ching AK, He M, Li JW, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 2014;25:335-49.

6. Liang HW, Wang N, Wang Y, Wang F, Fu Z, et al. Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122. J Hepatol 2016;64:278-91.

7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.

8. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77.

9. Papatheodoridis G V, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-16.

10. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013;57:399-408.

11. Yang F, Liu WB, Chen L, Tan XJ, Cao GW, et al. Anti-HBV treatment delays development and evolution of HCC. Academic Journal of Second Military Medical University 2014;35.

12. Tetsuya Hosaka, Antiviral Drug Cuts Cancer Risk in Hepatitis B, medpagetoday November 12, 2012.

13. Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy - A follow-up report of C-TEAM study. AASLD 2014:LB-30.

14. Jiang JN, Li SH, Su MH, Zhong SH, Wang BJ, et al. The clinical outcomes of the CHB and LC patient treated with long term nucleos(t)ide analogs under whole-course management: a real-life cohort study. J Hepatol 2014;60:S361-522.